NASDAQ:VBIV VBI Vaccines (VBIV) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free VBIV Stock Alerts $0.61 +0.01 (+0.91%) (As of 05:27 PM ET) Add Compare Share Share Today's Range$0.58▼$0.6250-Day Range$0.56▼$0.9252-Week Range$0.45▼$3.47Volume113,512 shsAverage Volume378,510 shsMarket Capitalization$17.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get VBI Vaccines alerts: Email Address VBI Vaccines MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.30% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment-0.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.39) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.04 out of 5 starsMedical Sector807th out of 910 stocksPharmaceutical Preparations Industry382nd out of 426 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for VBI Vaccines. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.30% of the float of VBI Vaccines has been sold short.Short Interest Ratio / Days to CoverVBI Vaccines has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VBI Vaccines has recently decreased by 4.56%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVBI Vaccines does not currently pay a dividend.Dividend GrowthVBI Vaccines does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for VBI Vaccines is -0.75. Previous Next 2.0 News and Social Media Coverage News SentimentVBI Vaccines has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for VBI Vaccines this week, compared to 1 article on an average week.Search Interest12 people have searched for VBIV on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VBI Vaccines insiders have not sold or bought any company stock.Percentage Held by Insiders10.35% of the stock of VBI Vaccines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.26% of the stock of VBI Vaccines is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VBI Vaccines are expected to grow in the coming year, from ($1.39) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVBI Vaccines has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About VBI Vaccines Stock (NASDAQ:VBIV)VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.Read More VBIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VBIV Stock News HeadlinesApril 18, 2024 | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.comApril 16, 2024 | businesswire.comVBI Vaccines Reports Full Year 2023 Financial ResultsApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 11, 2024 | businesswire.comVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 11, 2024 | investing.comVBI Vaccines secures $2 million in direct offeringApril 9, 2024 | businesswire.comVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 3, 2024 | businesswire.comVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaApril 2, 2024 | msn.comVBI Vaccines expands collaboration with Canadian governmentApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 2, 2024 | businesswire.comVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformMarch 31, 2024 | finance.yahoo.comVBI Vaccines Inc. (VBIV)March 22, 2024 | finance.yahoo.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsFebruary 15, 2024 | bizjournals.comNorth Carolina biotech inks $30M deal to expand its global pipelineFebruary 14, 2024 | msn.comVBI signs deal to sell manufacturing capabilities, certain assets with Brii BiosciencesFebruary 14, 2024 | finance.yahoo.comStrategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI VaccinesFebruary 14, 2024 | benzinga.comWhy Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketFebruary 14, 2024 | finance.yahoo.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 14, 2024 | businesswire.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 13, 2024 | markets.businessinsider.comBrii Biosciences To Buy VBI's IP Rights In BRII-179February 13, 2024 | prnewswire.comBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial SuppliesFebruary 7, 2024 | msn.comVBI Vaccines Secures Forbearance Agreement ExtensionsNovember 20, 2023 | finance.yahoo.comVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingNovember 14, 2023 | msn.comVBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63MNovember 14, 2023 | finance.yahoo.comVBI Vaccines Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramSeptember 30, 2023 | yahoo.comThese Are the Side Effects You Can Expect From the New COVID Vaccine, According to ImmunologistsSeptember 27, 2023 | msn.comVBI Vaccines’ pan-coronavirus vaccine candidate produced broad protection against COVID variants of concernSee More Headlines Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2023Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VBIV CUSIPN/A CIK764195 Webwww.vbivaccines.com Phone(617) 830-3031FaxN/AEmployees190Year Founded2001Profitability EPS (Most Recent Fiscal Year)($11.6824) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,840,000.00 Net Margins-1,069.29% Pretax Margin-1,069.29% Return on Equity-234.77% Return on Assets-47.11% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.37 Sales & Book Value Annual Sales$8.68 million Price / Sales1.94 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book1.85Miscellaneous Outstanding Shares28,430,000Free Float25,489,000Market Cap$16.81 million OptionableOptionable Beta1.93 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Jeffery R. Baxter FCMA (Age 63)President, CEO & Director Comp: $908.06kDr. David Evander Anderson (Age 54)Chief Scientific Officer Comp: $534.25kDr. Francisco Diaz-Mitoma FRCPC (Age 69)M.D., Ph.D., Chief Medical Officer Comp: $544.52kMs. Nell Beattie (Age 36)CFO, Head of Corporate Development & Director Nicole AndersonDirector of Corporate Communications & Investor RelationsMs. Athena Kartsaklis (Age 59)Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer Mr. Avi Mazaltov (Age 62)Global Head of Manufacturing & GM of SciVac Mr. Misha NossovSenior VP of Global Commercial Supply Strategy & Head of EuropeMr. T. Adam Buckley (Age 48)Senior Vice President of Business Development Mr. John Robert Dillman (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsTraws PharmaNASDAQ:TRAWCocrystal PharmaNASDAQ:COCPKiora PharmaceuticalsNASDAQ:KPRXEdesa BiotechNASDAQ:EDSANanoViricidesNYSE:NNVCView All CompetitorsInsidersSteven GillisBought 609,090 shares on 7/10/2023Total: $1.00 M ($1.65/share)View All Insider Transactions VBIV Stock Analysis - Frequently Asked Questions How have VBIV shares performed in 2024? VBI Vaccines' stock was trading at $0.5875 at the beginning of 2024. Since then, VBIV shares have increased by 3.6% and is now trading at $0.6085. View the best growth stocks for 2024 here. When is VBI Vaccines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VBIV earnings forecast. How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc. (NASDAQ:VBIV) posted its quarterly earnings results on Monday, March, 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to the consensus estimate of $1.98 million. VBI Vaccines had a negative trailing twelve-month return on equity of 234.77% and a negative net margin of 1,069.29%. When did VBI Vaccines' stock split? VBI Vaccines's stock reverse split on Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie (). How do I buy shares of VBI Vaccines? Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VBIV) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
